Status:
RECRUITING
iTBS for Acute Ischemic Stroke After Thrombectomy
Lead Sponsor:
Yi Yang
Conditions:
Ischemic Stroke
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The goal of this randomized, single-blind, parallel-controlled clinical trial is to evaluate the efficacy and safety of intermittent theta burst stimulation (iTBS) as an adjunctive therapy for acute a...
Eligibility Criteria
Inclusion
- 1\) Age 18-85 years, regardless of gender.
- 2\) Acute ischemic stroke caused by occlusion of the anterior circulation large vessels (internal carotid artery, M1 or M2 segment of the middle cerebral artery), verified by CTA or DSA.
- 3\) Mechanical thrombectomy (MT) performed within 24 hours of symptom onset.
- 4\) Successful Reperfusion: Post-MT eTICI score ≥ 2b.
- 5\) NIHSS score 5-25 at 24 hours post-MT, with ≥2 points in at least one limb.
Exclusion
- 1\) Pre-stroke modified Rankin Scale (mRS) score ≥2.
- 2\) PH2-type intracranial hemorrhage on brain CT post-MT.
- 3\) Patients who underwent intracranial stent placement during MT.
- 4\) Contraindications to iTBS: History of epilepsy or seizures, implanted cardiac pacemakers, cochlear implants, or other electronic/magnetic-sensitive devices.
- 5\) Severe consciousness impairment, cognitive dysfunction, or psychiatric disorders preventing compliance with iTBS.
- 6\) Expected survival \<3 months due to other medical conditions or inability to complete follow-up for any reason.
- 7\) Participation in another interventional study.
- 8\) Any other condition deemed unsuitable for enrollment by the investigator.
Key Trial Info
Start Date :
April 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
178 Patients enrolled
Trial Details
Trial ID
NCT06941961
Start Date
April 25 2025
End Date
August 1 2026
Last Update
April 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Hospital of Jilin University
Changchun, Jilin, China, 130000